CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire•02/11/2026•16:01 ET
0
Key Highlights
- ➤CASGEVY revenue reached $99 million in Q3 2026, up 30% quarter-over-quarter
- ➤CASGEVY revenue was nearly six times higher than Q3 2025
- ➤FDA granted CTX310 RMAT designations for severe hypertriglyceridemia and elevated LDL-C
- ➤CRISPR completed enrollment in the Phase 2 CTX611 knee-replacement trial
- ➤Cash, equivalents, and marketable securities totaled $2,276.6 million at September 30
Expert Statements
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“The third quarter marked meaningful progress for CRISPR Therapeutics”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease.”
Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics
“With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.”
– CASGEVY(®) revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 –
– CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older –
Get started
Create a free account to read the full story.